Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience

BackgroundCholangiocarcinoma management is constantly being updated in view of existing evidence in order to establish practice guidelines and consensus statements. However, the available treatment guidelines to optimize outcomes for cholangiocarcinoma patients who require liver transplantation are...

Full description

Bibliographic Details
Main Authors: Maen Abdelrahim, Abdullah Esmail, Jiaqiong Xu, Godsfavour Umoru, Hadeel Al-Rawi, Ashish Saharia, Ala Abudayyeh, David Victor, Robert McMillan, Sudha Kodali, Rafik M. Ghobrial
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
cholangiocarcinoma
hepatocellular carcinoma
gemcitabine
cisplatin
immunotherapy
liver transplantation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.908687/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.908687/full

Similar Items